Our aim was to conduct a systematic review and meta-analysis to examine the efficacy and safety of oliceridine in patients with postoperative pain.Four databases were searched from the beginning of...

Background and Objective: Deficiency of vitamin D could be a major cause of colon cancer as suggested as early as 1980 by Drs. Cedric and Frank Garland of the University of California and has recently been underscored by a large European case control

Background. Neuropathic pain is a complex sort of pain that is detrimental to individuals health, both physically and mentally, but merely a small portion of them could witness pain alleviation. Mirogabalin, by distinctive binding characteristics of voltage-gated calcium channels, has won approval from the Japanese authority as a third member of gabapentinoids in Japan. Our review was aimed at encompassing the bulk of clinical research on mirogabalin, which included clinical trials, special considerations, coadministration studies, case reports, and cost-effectiveness studies. Methods. A review was carried out on a series of platforms, such as PubMed, MEDLINE, and Scopus, up to December 2021 using the keywords as follows: mirogabalin OR mirogabalin besylate OR Tarlige OR DS-5565 AND neuropathic pain OR Neuropathy. Results. Mirogabalin demonstrated analgesic activity and manageable adverse reactions and provides a new alternative for individuals with PHN or DPNP in 3 phase II and 4 III trials. Mirogabalin alleviated pain markedly in comparison with placebo. Administration of mirogabalin on a long-term basis is a flexible dosage regimen for patients with PHN. It is noteworthy that mirogabalin should be administrated cautiously when combined with probenecid and cimetidine on account of a slight increase in pharmacodynamics effects of mirogabalin. Conclusion. The development of mirogabalin allows further optimization of individual treatment strategies so as to provide more therapeutic choices in this medical domain.

Background/Aims: The study aimed to investigate the interactions of genetic variants in the leptin receptor (LEPR) gene with lipid profile changes following a high-carbohydrate/low-fat (HC/LF) diet in a Chinese Han population. Methods: Fifty-six healthy young subjects were given washout diets, followed by HC/LF diets consisting of 15% fat and 70% carbohydrate for 6 days. Serum lipid profiles and insulin levels before and after HC/LF diets were analyzed. Results: Statistically elevated high-density lipoprotein cholesterol (HDL-C), apolipoprotein A-1 (apoA-I), and insulin levels were only observed in the GG genotype of LEPR Lys109Arg but not in the A carriers after HC/LF diet. When gender was taken into account, significantly increased HDL-C, apoA-I, and insulin levels were found in women with the GG genotype. Moreover, lower low-density lipoprotein cholesterol (LDL-C) and higher insulin levels were only observed in subjects with the GG genotype of LEPR Gln223Arg, while higher HDL-C and apoA-I were only found in the A allele carriers. Additionally, the lower LDL-C and body mass index (BMI), and higher HDL-C and insulin levels were only observed in subjects with the GG genotype of LEPR Lys656Asn. Conclusions:LEPR polymorphisms contribute to the heterogeneities in BMI, LDL-C, and HDL-C responsiveness that are induced by a HC/LF diet in healthy young Chinese adults.

Introduction: To evaluate the recovery quality between remimazolam and propofol after general anesthesia surgery.Methods: We included eligible randomized controlled trials (RCTs) in EMBASE, PubMed, Cochrane Central, Scopus, and Web of Science up to June 26, 2024 for comparison the recovery quality of remimazolam and propofol after general anaesthesia. The primary outcomes were the total Quality of Recovery-15 (QoR-15) and five dimensions of QoR-15 on postoperative day 1 (POD1). Secondary outcomes were adverse events, the Quality of Recovery-40 (QoR-40) on POD1, and the intraoperative and postoperative time characteristics.Results: Thirteen RCTs with a total of 1,305 patients were included in this meta-analysis. Our statistical analysis showed that remimazolam group had higher QoR-15 score on POD1, with no significant difference (Mean Difference (MD) = 1.24; 95% confidence interval (CI), [−1.67–4.15]; I²= 75%;P = 0.41). In the five dimensions of QoR-15, remimazolam group was superior to propofol group in terms of physical independence (MD = 0.79; 95% CI [0.31–1.27]; I² = 0%;P = 0.001). Remimazolam group was lower than propofol group in incidence of hypotension (Risk Ratio (RR) = 0.48; 95% CI [0.40–0.59]; I²= 14%;P < 0.00001), bradycardia (RR = 0.18; 95% CI [0.08–0.38]; I²= 0%;P < 0.0001) and injection pain (RR = 0.03; 95% CI [0.01–0.12]; I²= 48%;P < 0.00001), respectively. The intraoperative and postoperative time characteristics and the QoR-40 were similar in the two groups.Conclusions: Our analysis showed that the recovery quality of the remimazolam group after general anaesthesia was similar to propofol group, while the incidence of adverse events was low in remimazolam group. As a potential anesthetic, remimazolam can be used in place of propofol for surgical general anesthesia.

The in situ lactate oxidase (LOx) catalysis is highly efficient in reducing oxygen to H₂O₂ due to the abundant lactate substrate in the hypoxia tumor microenvironment. Dynamic therapy, including chemodynamic therapy (CDT), photodynamic therapy (PDT), and enzyme dynamic therapy (EDT), could generate reactive oxygen species (ROS) including ·OH and ¹O₂ through the disproportionate or cascade biocatalytic reaction of H₂O₂ in the tumor region. Here, we demonstrate a ROS-based tumor therapy by integrating LOx and the antiglycolytic drug Mito-LND into Fe₃O₄/g-C₃N₄ nanoparticles coated with CaCO₃ (denoted as FGLMC). The LOx can catalyze endogenous lactate to produce H₂O₂, which decomposes cascades into ·OH and ¹O₂ through Fenton reaction-induced CDT and photo-triggered PDT. Meanwhile, the released Mito-LND contributes to metabolic therapy by cutting off the source of lactate and increasing ROS generation in mitochondria for further improvement in CDT and PDT. The results showed that the FGLMC nanoplatform can multifacetedly elevate ROS generation and cause fatal damage to cancer cells, leading to effective cancer suppression. This multidirectional ROS regulation strategy has therapeutic potential for different types of tumors.